Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells

Cancer Prevention Research

Volumn 8, Issue 11, 2015, Pages 1036-1044

  Lesinski, Gregory B ^a   Reville, Patrick K ^a   Mace, Thomas A ^a   Young, Gregory S ^b   Ahn Jarvis, Jennifer ^b   Thomas Ahner, Jennifer ^a   Vodovotz, Yael ^a,b   Ameen, Zeenath ^a   Grainger, Elizabeth ^a   Riedl, Kenneth ^a,b   Schwartz, Steven ^a,b   Clinton, Steven K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA GLUCOSIDASE; CD14 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; COLONY STIMULATING FACTOR 1; CXCL11 CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR; FRACTALKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; ISOFLAVONE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; NERVE GROWTH FACTOR; SOY ISOFLAVONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CHEMOKINE; ISOFLAVONE DERIVATIVE; SOYBEAN PROTEIN;

ADULT; AGED; ALMOND; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BREAD; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; MALE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; POWDER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SOYBEAN MEAL; SUPPRESSOR CELL; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; BLOOD; CARCINOGENESIS; CHEMISTRY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DIET; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; METABOLISM; NUT; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROSTATIC NEOPLASMS; SOYBEAN; TH17 CELL; TUMOR RECURRENCE;

BETA-GLUCOSIDASE; BIOMARKERS; BREAD; CARCINOGENESIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DIET; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; ISOFLAVONES; MALE; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; NUTS; PHENOTYPE; PROSTATIC NEOPLASMS; PRUNUS DULCIS; SIALIC ACID BINDING IG-LIKE LECTIN 3; SOYBEAN PROTEINS; SOYBEANS; TH17 CELLS; TH2 CELLS;

EID: 84946124340     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0464     Document Type: Article

References (50)

1. Messina M. Western soy intake is too low to produce health effects. Am J Clin Nutr 2004;80:528-9; author reply 529-30.
2. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1-12.
3. Trottier G, Bostrom PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol 2010;7:21-30.
4. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999;129:1628-35.
5. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
6. Zuniga KE, Clinton SK, Erdman JW Jr. The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model. Cancer Prev Res 2013;6:548-57.
7. Bosland MC, Kato I, Zeleniuch-Jacquotte A, Schmoll J, Enk Rueter E, Melamed J, et al. Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA 2013;310:170-8.
8. Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, et al. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr 2010;140:1192S-204S.
9. Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, et al. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol 2010;8:3-13.
10. Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, et al. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007;59:163-8.
11. Van Die MD, Bone KM, Williams SG, Pirotta MV. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int 2014;113:E119-30.
12. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:2690-4.
13. Kranse R, Dagnelie PC, Van Kemenade MC, De Jong FH, Blom JH, Tijburg LB, et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer 2005;113:835-40.
14. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 2003;61:117-31.
15. Wang S, De Groff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003;133:2367-76.
16. Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007;18:408-17.
17. Pavese JM, Krishna SN, Bergan RC. Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis. Am J Clin Nutr 2014;100:431S-6S.
18. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93.
19. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014;23:847-56.
20. Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013;19:50-8.
21. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
22. Condamine T, Gabrilovich DI. Molecular mechanisms regulatingmyeloidderived suppressor cell differentiation and function. Trends Immunol 2011;32:19-25.
23. Fox SB, Launchbury R, Bates GJ, Han C, Shaida N, Malone PR, et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. Prostate 2007;67:623-9.
24. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
25. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010;70:443-55.
26. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al. Enhanced functionality of CD4+CD25 (high) FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40.
27. Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus post-vaccination. Cancer Immunol Immunother 2011;60:197-206.
28. Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012;1:152-61.
29. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castrationresistant metastatic prostate cancer. Cancer Immunol Immunother 2014;63:1177-87.
30. Ahn-Jarvis JH, Clinton SK, Grainger EM, Riedl KM, Schwartz SJ, Lee M-L, et al. Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer. Cancer Prev Res 2015;8:1045-54.
31. Ahn-Jarvis JH, Riedl KM, Schwartz SJ, Vodovotz Y. Design and selection of soy breads used for evaluating isoflavone bioavailability in clinical trials. J Agric Food Chem 2013;61:3111-20.
32. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 (+) T cells from patients with GI malignancy. Cancer Immunol Immunother 2011;60:1269-79.
33. Mace TA, Ameen Z, Collins A, Wojcik SE, Mair M, Young GS, et al. Pancreatic cancer associated stellate cells promote differentiation of myeloidderived suppressor cells in a STAT3-dependent manner. Cancer Res 2013;73:3007-18.
34. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-87.
35. Gordon A, Glazko G, Qui X, Yakovlev A. Control of the mean number of false discoveries, Bonferroni and stability of multiple testing. Ann Appl Stat 2007;1:179-90.
36. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000;130:2073S-85S.
37. Sakai T, Kogiso M. Soy isoflavones and immunity. J Med Invest 2008;55:167-73.
38. Yum MK, Jung MY, Cho D, Kim TS. Suppression of dendritic cells' maturation and functions by daidzein, a phytoestrogen. Toxicol Appl Pharmacol 2011;257:174-81.
39. Guo TL, McCay JA, Zhang LX, Brown RD, You L, Karrow NA, et al. Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. J Nutr 2001;131:3251-8.
40. Kogiso M, Sakai T, Mitsuya K, Komatsu T, Yamamoto S. Genistein suppresses antigen-specific immune responses through competition with 17beta-estradiol for estrogen receptors in ovalbumin-immunized BALB/c mice. Nutrition 2006;22:802-9.
41. Santell RC, Kieu N, Helferich WG. Genistein inhibits growth of estrogenindependent human breast cancer cells in culture but not in athymic mice. J Nutr 2000;130:1665-9.
42. Yellayi S, Naaz A, Szewczykowski MA, Sato T, Woods JA, Chang J, et al. The phytoestrogen genistein induces thymic and immune changes: a human health concern? Proc Natl Acad Sci USA 2002;99:7616-21.
43. Yellayi S, Zakroczymski MA, Selvaraj V, Valli VE, Ghanta V, Helferich WG, et al. The phytoestrogen genistein suppresses cell-mediated immunity in mice. J Endocrinol 2003;176:267-74.
44. Guo TL, White KL Jr, Brown RD, Delclos KB, Newbold RR, Weis C, et al. Genistein modulates splenic natural killer cell activity, antibody-forming cell response, and phenotypic marker expression in F (0) and F (1) generations of Sprague-Dawley rats. Toxicol Appl Pharmacol 2002;181:219-27.
45. Guo TL, Zhang XL, Bartolucci E, McCay JA, White KL Jr, You L. Genistein and methoxychlor modulate the activity of natural killer cells and the expression of phenotypic markers by thymocytes and splenocytes in F0 and F1 generations of Sprague-Dawley rats. Toxicology 2002;172:205-15.
46. Cooke PS, Selvaraj V, Yellayi S. Genistein, estrogen receptors, and the acquired immune response. J Nutr 2006;136:704-8.
47. Hillman GG, Singh-Gupta V, Runyan L, Yunker CK, Rakowski JT, Sarkar FH, et al. Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury. Radiother Oncol 2011;101:329-36.
48. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004;53:422-30.
49. Santilli G, Piotrowska I, Cantilena S, Chayka O, D'Alicarnasso M, Morgenstern DA, et al. Polyphenol E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res 2013;19:1116-25.
50. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res 2012;5:205-15.